# Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma

## TL;DR

A rare testicular cancer was successfully treated with a chemotherapy drug used for ovarian cancer, leading to long-term remission.

## Contribution

This is the first reported case of using bevacizumab in treating ovarian-type serous adenocarcinoma of the testis.

## Key findings

- The patient achieved regression of lesions after bevacizumab-based chemotherapy.
- The patient remained progression-free for over 3 years following treatment.
- Bevacizumab may be a viable treatment option for this rare disease.

## Abstract

Ovarian-type serous adenocarcinoma of the testis is an extremely rare malignant disease, and experience and evidence regarding its treatment are lacking. Herein, we describe the case of a 39-year-old man who presented with widespread metastasis in the retroperitoneal and pelvic lymph nodes after surgical resection of his right testicular tumor. Systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous adenocarcinoma, was administered, and retroperitoneal lymph node dissection and radiotherapy followed after the lesions regressed. The patient has had over 3 years of progression-free survival. This is the first case of a bevacizumab combination in this disease and indicates that bevacizumab may be an option for the treatment strategy of this rare disease.